Beyondspring Inc
NASDAQ:BYSI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Beyondspring Inc
Pre-Tax Income
Beyondspring Inc
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Beyondspring Inc
NASDAQ:BYSI
|
Pre-Tax Income
-$8.6m
|
CAGR 3-Years
38%
|
CAGR 5-Years
33%
|
CAGR 10-Years
-1%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Pre-Tax Income
$6.6B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
14%
|
CAGR 10-Years
0%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Pre-Tax Income
$9.8B
|
CAGR 3-Years
19%
|
CAGR 5-Years
42%
|
CAGR 10-Years
-8%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Pre-Tax Income
$9B
|
CAGR 3-Years
7%
|
CAGR 5-Years
2%
|
CAGR 10-Years
1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Pre-Tax Income
$4.6B
|
CAGR 3-Years
3%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Pre-Tax Income
$5.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
16%
|
|
Beyondspring Inc
Glance View
BeyondSpring, Inc. engages in the the development and commercialization of immuno-oncology cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. The company is headquartered in New York City, New York and currently employs 103 full-time employees. The company went IPO on 2017-03-09. The Company’s lead product Plinabulin, which is being studied as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Plinabulin product is a marine-derived small-molecule selective immunomodulating microtubule-binding agent (SIMBA) with a range of immune activities. Its Plinabulin has the immune defense protein, GEF-H1, which leads to two effects: a durable anti-cancer benefits due to the maturation of dendritic cells resulting in activation of tumor antigen-specific T-cells to target cancer cells and early-onset action in chemotherapy-induced neutropenia (CIN) prevention after chemotherapy by boosting the number of hematopoietic stem/progenitor cells (HSPCs).
See Also
What is Beyondspring Inc's Pre-Tax Income?
Pre-Tax Income
-8.6m
USD
Based on the financial report for Dec 31, 2025, Beyondspring Inc's Pre-Tax Income amounts to -8.6m USD.
What is Beyondspring Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-1%
Over the last year, the Pre-Tax Income growth was 2%. The average annual Pre-Tax Income growth rates for Beyondspring Inc have been 38% over the past three years , 33% over the past five years , and -1% over the past ten years .
